NCBP1
ENSG00000136937
Target class
Unclassified protein
Chromosome
9
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- NCBP1
- Gene name
- Nuclear cap binding protein subunit 1
- Gene symbol
- NCBP1
- Previous gene symbols
- NCBP
- Protein name
- Nuclear cap-binding protein subunit 1 (80 kDa nuclear cap-binding protein) (CBP80) (NCBP 80 kDa subunit)
- CBP80
- Sto1
- Gene biotype
- Protein coding
- Gene family
- MIF4G domain containing proteins
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 34.28
- Tissue specificity (Gini)
- 0.232
- Tissue specificity (tau)
- 0.581
- KEGG gene identifiers
- hsa:4686
- Protein interaction confidence
- 0.85512
- Protein interaction partners
- 191
- R-HSA-111367
- R-HSA-112382
- R-HSA-113418
- R-HSA-159227
- R-HSA-159230
- R-HSA-159231
- R-HSA-159236
- R-HSA-167152
- R-HSA-167158
- R-HSA-167200
- R-HSA-167242
- R-HSA-191859
- R-HSA-674695
- R-HSA-6803529
- R-HSA-6807505
- R-HSA-72086
- R-HSA-72163
- R-HSA-72165
- R-HSA-72187
- R-HSA-72203
- R-HSA-73856
- R-HSA-77588
- R-HSA-77595
- R-HSA-8851708
- R-HSA-9010553
And 5 more, listed on the interactive page.
- End position
- 97673748
- Start position
- 97633448
- Chromosome
- 9
- Strand
- Forward
- Nucleus . Cytoplasm . Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs. .
- Cytosol
- Nucleoplasm
- PubMed 19648179
- PubMed 17289661
- Tissue specificity (tau)
- 0.580904
- Expression inequality (Gini)
- 0.232199
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 34.28
- Cells - Cultured fibroblasts
- 33.22
- Testis
- 25.66
- Nerve - Tibial
- 23.11
- Ovary
- 21.33
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes34.28
- Cells - Cultured fibroblasts33.22
- Testis25.66
- Nerve - Tibial23.11
- Ovary21.33
- Cervix - Endocervix21.21
- Brain - Cerebellar Hemisphere21.05
- Thyroid20.8
- Uterus20.49
- Brain - Cerebellum19.97
- Vagina19.16
- Fallopian Tube19.02
- Cervix - Ectocervix18.96
- Bladder18.07
- Pituitary17.98
- Lung17.12
- Skin - Sun Exposed (Lower leg)16.98
- Artery - Coronary16.91
- Artery - Tibial16.8
- Skin - Not Sun Exposed (Suprapubic)16.62
- Prostate16.54
- Artery - Aorta16.52
- Esophagus - Mucosa15.53
- Colon - Transverse15.52
- Small Intestine - Terminal Ileum15.44
And 29 more, listed on the interactive page.
- GO:0000184
- GO:0000245
- GO:0006370
- GO:0006401
- GO:0006406
- GO:0006408
- GO:0006446
- GO:0008334
- GO:0008380
- GO:0016071
- GO:0030307
- GO:0031442
- GO:0042789
- GO:0048026
- GO:0051607
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005846
- GO:0034518
- GO:1990904
- GO:0000339
- GO:0000340
- GO:0003723
- GO:0005515
- GO:0060090
Related records
Trials (21)
- A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
- ABTECT - Maintenance
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
- ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
- ABX464 First in Man Study
- ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
- ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
- Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
- Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
- Food Effect on Pharmacokinetic Parameters of ABX464
- Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
- Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
- Safety, PK and PD Study of ABX464 in Untreated HIV Patients
- Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
- Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
- Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Drugs (1)
- Obefazimod Cap binding complex modulator